Avalo Therapeutics, which is developing targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases, appointed its Chief Scientific Officer Garry Neil as its CEO.
Photo: Garry Neil, CEO of Avalo Therapeutics
The company also named Chris Sullivan, chief accounting officer, as its chief financial officer.
Avalo said CEO Mike Cola and CFO Schond Greenway have stepped away from their prior roles to pursue other interests.
“The company made substantial progress under their leadership, and it is now reaching an exciting inflection point given the recent and upcoming data readouts,” said Steven Boyd, chairman of the board of Avalo Therapeutics. “Looking at the future of Avalo, we believe that Garry and Chris will be the right team to execute an optimal strategy focused on prioritizing our most promising programs allowing for greater operational achievement, opportunities for business development, and ultimately increased shareholder value.”
Neil also serves as the chairman of the board of Arena Pharmaceuticals, an approximately $6 billion Nasdaq-listed biotechnology company. He is a member of the board of the Center for Discovery and Innovation at Hackensack Meridian Health. Prior to joining Avalo, Neil served as chief scientific officer of Aevi Genomic Medicine and held a number of senior positions in the pharmaceutical industry, academia, and venture capital.
Author: Rare Daily Staff
Stay Connected
Sign up for updates straight to your inbox.